BMS’s Opdivo and Yervoy colorectal cancer trials show promising results
BMS presented this data supporting the use of immune checkpoint inhibitors (ICIs) in combination in patients with newly diagnosed advanced colorectal cancer subtypes at the ASCO Gastrointestinal Cancer Symposium. Credit: Tada Images / Shutterstock. On January 22, BMS announced encouraging findings from the CheckMate -8HW clinical trial, showing that the combination of Opdivo (nivolumab) and […]
BMS’ Opdivo regimen shows promise in colorectal cancer clinical trials
BMS’ Opdivo plus Yervoy significantly improved progression-free survival in patients with MSI-H/dMMR metastatic colorectal cancer. Credit: Bristol-Myers Squibb Company. bristol myers squib (BMS) is a Phase III CheckMate-8HW clinical trial combining Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment option for microsatellite-high instability (MSI-H) or mismatch repair deficiency (dMMR). reported promising data. Metastatic colorectal […]
Bristol-Myers Squibb launches Kibosh into clinical trials for colorectal cancer candidate
Photo: Bristol-Myers Squibb Building in Munich / iStock Tati Campero Bristol-Myers Squibb is discontinuing a clinical trial studying a combination of Opdivo (nivolumab) and leratorimab, called Opdurag, in patients with stable microsatellite metastatic colorectal cancer. Data from a Phase III trial of the combination, known as Relativity-123, was reviewed by an independent data monitoring board […]